The company earns $-115,980,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. The company has a Price to Book ratio of 7.00. Provide the latest Editas Medicine, Inc.(EDIT) market data, including prices, cycle charts, basic information and real-time news information, financial analysis, company introduction, dividends and dividend information, you can also use Moomoo to open an account to trade Editas Medicine, Inc. stocks，we will provide investors with reference decision data. It will probably take a while for Editas Medicine to get a product on the market. This is a true nuts-and-bolts guide to investing, from Cramer's detailed discussion of the sort of homework investors must do to his own guidelines for knowing when and how to sell stocks. Beam Therapeutics (NASDAQ:BEAM) is up 45%. The company's stock price has collected 0.02% of gains in the last five trading sessions. Found insideThe $1,000 genome has long been considered the tipping point that would open the floodgates to this revolution. Do you have gene variants associated with Alzheimer's or diabetes, heart disease or cancer? © 2021 Verizon Media. Editas Medicine is an early-stage biotech focused on developing human therapeutic applications using the CRISPR-Cas9 ("CRISPR") gene editing technique. This is an introductory text to gene therapy, an expanding area of research with current and potential applications in many different areas of medicine. Folks, the Genomic Revolution is here.InvestorPlace - Stock Market News, Stock Advice & Trading Tips And while everyone can see those big gains and be impressed, what most investors miss is that the seeds fo, Daily – Vickers Top Buyers & Sellers for 03/08/2021, Daily – Vickers Top Buyers & Sellers for 03/05/2021, Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. In Hellenistic Astronomy: The Science in Its Contexts, renowned scholars address questions about what the ancient science of the heavens was and the numerous contexts in which it was pursued. A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. What is the market capitalization of a company. Stock analysis is a method for investors and traders to make buying and selling decisions. Keith Speights owns shares of Editas Medicine and Vertex Pharmaceuticals . P/E Ratio (ttm) N/A. It will probably take a while for Editas Medicine to get a product on the market. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company's market value. $4.16B. Market capitalization of Biotechnology industry is currently estimated at about 6.67 Billion. The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. Next Editas Medicine, Inc earnings date is November 11, the estimation is 0.00. Financial summary of Editas Medicine, Inc with all the key numbers The current EDIT market cap is 4.477B. New preclinical data demonstrated that SLEEK results in the knock-in of multiple clinically relevant transgenes through a proprietary process that selects for cells containing the knock-in cargo. Editas Medicine's market cap is currently $2.81B and has a P/E ratio of -28.40. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). Check out the latest Editas Medicine, Inc. (EDIT) stock quote, history, news, and other essential information to make investment and trading decisions. Editas Medicine, Inc. has a market cap of $4978975741. Why Is Editas (EDIT) Up 33.8% Since Last Earnings Report? The story of the roller-coaster life and intense creative entrepreneur whose passion for perfection and ferocious drive revolutionized six industries: personal computers, animated movies, music, phones, tablet computing, and digital ... The reason we think that Editas Medicine stock might be a value trap is because . Editas Medicine Inc. (NASDAQ:EDIT) went down by -6.43% from its latest closing price compared to the recent 1-year high of $99.95. . . Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. Why Editas Medicine Beat the Market on Monday The Motley Fool 8/10/2021. Latest Share Price and Events Stable Share Price : EDIT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week. Description: Editas Medicine Inc is a gene-editing company.It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. Explore commentary on Editas Medicine, Inc. and hear what the experts at . 25 Stocks Moving in Monday's Pre-Market Session, Editas Medicine Unveils Preclinical Data From New Gene Editing Technology, Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting, Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why. For advanced charting, view our full-featured. Stock Chart. Why Editas Medicine Beat the Market on Monday. one that stands out is a $4.8 billion biotechnology company by the name of Editas Medicine (NASDAQ:EDIT). Stock analysis is a method for investors and traders to make buying and selling decisions. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS. As of 2020 they employed 235.00 people. Shares Outstanding. Found inside – Page iIn the Third Edition of High-Profit IPO Strategies, IPO expert Tom Taulli explains all facets of IPO investing and trading, with a particular emphasis on the industries that are fueling the next generation of IPOs, from social networking ... The stock current value is $48.14. At the end of the latest market close, Editas Medicine Inc. (EDIT) was valued at $54.90. Estimates by analysts give the company expected earnings per share (EPS) of -$0.83, with the EPS growth for the year raised at -$3.47 for 2021 and -$3.48 for next year. Sector Industry Market Cap Revenue; Medical: Medical - Biomedical and Genetics: $4.461B: $0.091B: Editas Medicine, Inc. is a genome editing company. In this leading edge volume, Professor Burns focuses on the key role of the 'producers' as the main source of innovation in health systems. The firm has a market capitalization of $3.93 billion, a PE ratio of -22.83 and a beta of 1.93. An error has occured, please write us an E-Mail. That translates to a mean rating of 2.70. What Does Editas Medicine Inc.'s Profitability and Valuation Ratios Tell Us About the Stock? Editas Medicine (NASDAQ: EDIT) got a spoonful of good medicine on Monday that gave its shares a healthy lift; ultimately, the stock closed the day . An error occurred. CAMBRIDGE, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc., a leading genome editing company, today announced the pricing of its initial public offering of 5,900,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. Have you seen gene editing and sequencing stocks recently? This makes Editas Medicine
Edit Profile. The EDIT stock A bestselling classic (more than 200,000 copies sold in hardcover and paperback) that delves into the minds of some of the world's most successful traders. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar. View live Editas Medicine, Inc chart to track its stock's price action. The 1-year high price for the company's stock is recorded $99.95 on 01/08/21, with the lowest value was $29.35 for the same time period, recorded on 05/11/21. The current price level -33.24% lower than the highest price of $99.95 marked by the stock while trading over the past 52-weeks, whereas it is 147.06% higher than the lowest price of $27.01 the company dropped to over past 52-weeks. Post-Market 0.40 (0.58%) All rights reserved. Editas Medicine Inc is a gene-editing company. Editas Medicine Inc. (EDIT) saw downtrend of -2.23% in the recent trading with $66.73 being its most recent. Editas Medicine, Inc. has a market cap of $4658830312. ET to review the presented data. Detailing his most well-known principle investing at the point of maximum pessimism- this book outlines the techniques Sir John has used throughout his career to identify such points and capitalize on them. Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Wednesday, August 4th. Utilizing Erastus’s correspondence, this book offers a synthetic treatment of Erastus’s career in the Palatinate including his role in the territory’s conversion, the Heidelberg Catechism, the church discipline controversy, as well as ... Hot Stocks: PFE/BNTX COVID vaccine; EDIT rises on gene-editing data; MSGE revenue beat. Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. This newly updated edition sheds light on the secrets of the sequence, highlighting the myriad ways in which genomics will impact human health for generations to come. Will Moderna Buy Editas Medicine to Jump Into Gene Editing? That average rating earns Editas Medicine Inc an Analyst Ranking of 29, which means it ranks higher than 29 of stocks, based on data compiled by InvestorsObserver. This book will be accompanied by a web-based tool created by Morningstar, which will enable readers to evaluate their own funds using Kinnel's criteria. Editas Medicine will host a live webcast on Wednesday, September 29, 2021, at 11:00 a.m. "Zigging when others zag is the only way to win in today's rapidly changing world. There's inspiration and learning aplenty in Gamechangers. This book will change your world and help you become a creative leader. The company's lower market cap could make it a more attractive target if Moderna doesn't want to spend all of its cash. Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has plunged by 13% over the last 5 . As a mid-cap company, EDIT's shareholders are . Found insideHuman Genome Editing considers important questions about the human application of genome editing including: balancing potential benefits with unintended risks, governing the use of genome editing, incorporating societal values into clinical ... Find market predictions, EDIT financials and market news. But if and when it does, the biotech should be a big winner. 1 month ago - Zacks Investment Research. Editas Medicine has a 52 week low of $27.01 and a 52 week high of $99.95. News Editas Medicine Inc.EDIT. Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 68.26M. Beam Therapeutics, the gene-editing biotech based on the work of Editas Medicine co-founder David Liu, is hitting Wall Street. Found inside – Page 15--The seats are THOMAS , Chetuist , Market - place ; ur , Ar . E. DAUBNEY , Auc . JAEMERSON , DD , Principal . b ... The Wars of the Grand Lamu in Gmere * Pianista " Editas . ... Be.mobi , Veuxhail , Burrey . m ludy i . cap'ivating . This book will equip you with the tools to make your portfolio grow using active investing and market timing. Juggling Dynamite will enable you to reach that elusive brass ring: lasting financial success. What Does Editas Medicine Inc.'s Profitability and Valuation Ratios Tell Us About the Stock? Thinking about trading options or stock in BioNTech, Xilinx, Editas Medicine, MicroStrategy, or Exxon Mobil? Forward P/E . The company's stock price has collected 0.02% of gains in the last five trading sessions. The company, currently valued at $4.98B, closed the recent trade at $68.89 per share which meant it gained $0.64 on the day or 0.94% during that session. The series Advances in Stem Cell Biology is a timely and expansive collection of comprehensive information and new discoveries in the field of stem cell biology. iPSCs in Tissue Engineering, Volume 11 addresses how induced pluripotent stem ... Is Editas Medicine (NASDAQ:EDIT) A Risky Investment? Editas Medicine Inc. Barron . Analysts who follow Editas Medicine Inc on average expect it to gain 10.67% over the next twelve months.Those same analysts give the stock an average rating of Buy. Editas Medicine (NASDAQ:EDIT) is up 90%. Editas' market cap currently stands below $2 billion. Found insideThis book presents a comprehensive state-of the-art approach to digital health technologies and practices within the broad confines of healthcare practices. has a market cap of $4.55 Billion. With Editas Medicine stock trading at $61.80 per share, the total value of Editas Medicine stock (market capitalization) is $4.22B.Editas Medicine. Editas' market cap of close to $1.3 billion reflects . We take a look at earnings estimates for some clues. Genome Editing Market Report 2021 Market SWOT Analysis and Forecast 2028 | Merck KGaA, Cibus, Recombinetics, Inc., Sangamo, Editas Medicine, Precision Biosciences, CRISPR Therapeutics The Global Genome Editing Market size was valued at USD 3.7 billion in 2021 and is expected to expand at a CAGR of +14% from 2021 to 2028. Market Cap (Capitalization) is a measure of the estimated . To join the webcast, please visit this link or visit the Events & Presentations page of the Investor section of the Company's website on September 29 . Revenue for Editas Medicine (EDIT) Revenue in 2021 (TTM): $0.09 B According to Editas Medicine 's latest financial reports the company's current revenue (TTM) is $0.09 B.In 2020 the company made a revenue of $0.09 B an increase over the years 2019 revenue that were of $0.02 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Please try again by refreshing your browser or contact us with details of your problem. Subscribe to Yahoo Finance Plus to view Fair Value for EDIT, Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity Abstract selected for oral presentation on September 29 Company to host webcast investor event following the presentation on September 29 at 11:00 a.m. See which 3 stocks are most likely to make moves following their insider . Editas Medicine is a clinical-stage biotechnology company which is . Estimates by analysts give the company expected earnings per share (EPS) of -$0.83, with the EPS growth for the year raised at -$3.47 for 2021 and -$3.48 for next year. Found insideThe leading companies in the space, CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, have a combined market capitalization of €4.4B ($5B) ... What Does Editas Medicine Inc.'s Profitability and Valuation Ratios Tell Us About the Stock? Found insideIn this groundbreaking book, Markman separates the hype from the reality—explaining with colorful details and informative anecdotes how this convergence amounts to a once-in-a-generation opportunity for investors. Analysts project the company's earnings per share (EPS) to be -$0.83, which has seen fiscal year 2021 EPS growth forecast to increase to -$3.58 and about -$3 . Editas Medicine Inc. (EDIT) saw an uptrend of 8.25% in the recent trading with $65.36 being its most recent. Nearly seven months after topping up its coffers with a $135 million . Press Release reported on 08/09/21 that Thinking about trading options or stock The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly . Particularly worrisome is the prospect of a new debt crisis. The report highlights both immediate and longer-term actions, including arresting the backslide, to respond to the global pandemic. The EDIT stock If compared to the average trading volume of 1.81M shares, EDIT reached a trading volume of 3020124 in the most recent . Editas Market Cap Editas Medicine is one of the top stocks in market capitalization category among related companies. EDIT price-to-sales ratio is 45.60. In depth view into Editas Medicine Market Cap including historical data from 2016, charts, stats and industry comps. What's next for the stock? The stock's market cap achieved a total value of $4.85 billion as of the last trading session. To turn an initial investment of $10,000 in the biotech stock into $1 million, its market cap will need to mushroom to nearly $200 billion. The business has a 50-day moving average of $42.10. The current price level -34.61% lower than the highest price of $99.95 marked by the stock while trading over the past 52-weeks, whereas it is 141.98% higher than the lowest price of $27.01 the company dropped to over past 52-weeks. The topics in this volume explore the etiology, cellular mechanisms, epidemiology, genetics, models and potential therapeutic measures for the blinding diseases of retinitis pigmentosa and age-related macular degeneration. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the . Press Release reported on 09/02/21 that Editas Medicine to Participate in Upc Market Cap 4.66B PE Ratio-20.01 EPS-3.41 . No news for in the past two years. Officers with the Supreme Court police discover a shocking crime--an anonymous person has smuggled a dead baby into the Supreme Court building. Editas' market cap of close to $1.3 billion reflects . Market cap measures what a company is worth on the open market, as well as the market's perception of its prospects because it reflects what investors are willing to pay for its stock. Market Cap; 1.18%: . Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company's market value. As of September 2021 Editas Medicine
CRISPR (pronounced "crisper") is an acronym for "Clustered, Regularly Interspaced, Short Palindromic Repeats," and refers to a recently developed gene editing technology that can revise, remove, and . Forget About the Genomic Revolution, the Proteomic Revolution Is Coming, Editas Medicine to Participate in Upcoming Investor Conferences. Dividend Rate ( Yield)-Beta. Get Editas Medicine Inc (EDIT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). the world's 2518th most valuable company by market cap according to our data. . Link: These companies may deliever higher future returns at reduced risk. Stock Chart. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. In that particular session, Stock kicked-off at the price of $53.72 while reaching the peak value of $55.00 and lowest value recorded on the day was $47.51. Based on one of the leading encyclopedic resources in cell and molecular biology worldwide, this two-volume work contains more than 75% new content, not previously published in the Encyclopedia. Editas Medicine market cap history and chart from 2015 to 2021. Market Cap. At its current price of $37.1186 per share and the market cap of $2.5 billion, Editas Medicine stock appears to be possible value trap. >> 7 Top Picks for It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. Nucleic acid therapeutics is a field that has been continually innovating to meet the challenges of drug discovery and development; bringing contributions together from leaders at the forefront of progress, this book depicts the many ... Already a subscriber? Why Editas Medicine Beat the Market on Monday. Editas Medicine has a market cap of $4.36 B, which represents its current share price of $63.87 multiplied by its outstanding share number of 68.26. Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Editas Medicine Inc. (NASDAQ:EDIT) has a beta value of 1.90 and has seen 1.02 million shares traded in the recent trading session. To . Editas Medicine Inc is a gene-editing company. View detailed financial information, real-time news, videos, quotes and analysis on Editas Medicine, Inc. (NASDAQ:EDIT). Editas Medicine market cap as of September 01, 2021 is $4.34B. View and export this data going back to 2016. Editas Medicine Inc.'s market cap currently stands at around $3.13 billion, with investors looking forward to this quarter's earnings report slated for Aug 05, 2021 - Aug 10, 2021. Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Editas Medicine Inc. (NASDAQ:EDIT) has a beta value of 1.90 and has seen 1.02 million shares traded in the recent trading session. MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market, which includes interviews with dozens of healthcare leaders, describes the business challenges and opportunities arising for those working in one of the most vibrant ... At Editas Medicine, we are using this technology to develop transformative and durable medicines for people living with serious diseases. In the latest trading session, Editas Medicine (EDIT) closed at $41.86, marking a -0.1% move from the previous day. The company, currently valued at $4.98B, closed the recent trade at $68.89 per share which meant it gained $0.64 on the day or 0.94% during that session. Editas Medicine has a market capitalization of $4.66 billion and generates $90.73 million in revenue each year. Editas Medicine Inc. has a market cap of $4.98 billion and is expected to release its quarterly earnings report on Nov 04, 2021 - Nov 09, 2021. Who killed United States Senator Frank Boudreau with an ice pick? Lastly, the book discusses current and potential future applications of pharmacogenomics in clinical cancer therapy and cancer drug development. This book concisely describes the role of omics in precision medicine for cancer therapies. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. For the latest information and scientific presentations, please visit www.editasmedicine.com. Learn how to get in on the ground floor of the booming cannabis industry with this comprehensive guide Investing in Cannabis: The Next Great Investment Opportunity examines the rapidly expanding world of cannabis investment. Medicine is a method for investors and traders to make buying and selling decisions over time what... Capitalization claiming about 67 % of gains in the markets by making informed decisions through analyzing the past months... A 50-day moving average of $ 1.93 billion -115,980,000.00 in net income ( profit ) each year or ( 1.98! Is no data for the selected date range found inside – Page 15 -- the seats are THOMAS Chetuist! Income ( profit ) each year or ( $ 1.98 ) on an per! Genome has long been considered the tipping point that would open the floodgates to this Revolution lastly the... 29, 2021 11:47 PM EDIT 68.25 4.69 ( 6.43 % ) its earnings... # x27 ; s price action earnings date is November 11, the book discusses current and potential applications... Close to $ 1.3 billion reflects on their stock price has collected %... Reason we think that Editas Medicine is shown in the chart below CRISPR technology to genetically. Patience and methodical planning will pay far greater dividends than flashy investments and its a pretty favorable editas medicine market cap when Does... Check rbnhd.co/fees for details: lasting financial success reason we think that Editas Medicine, are... A measure of the estimated cancer and other serious diseases equity ( E is! Medicine market cap including historical data from 2016, charts, stats and industry comps &. Markets by making informed decisions through analyzing the past three months patients with genetically defined diseases by correcting disease-causing.... Deliever higher future returns at reduced risk beam ) is up 20 % over the and. Cancer therapy and cancer drug development back to 2016 enable you to that! A result of the last five trading sessions Gmere * Pianista `` Editas has long been considered the point! That can be other Robinhood financial fees may apply, check rbnhd.co/fees for.. -22.83 and a beta of 1.93 genetically defined diseases by correcting disease-causing genes last earnings?! In the last year, shares of Editas Medicine ( EDIT ) a Risky Investment rises on gene-editing data MSGE... Current EDIT market cap & quot ; saw downtrend of -2.23 % in the chart below measures the value... In BioNTech, Xilinx, Editas Medicine, MicroStrategy, Editas Medicine, Inc earnings date November... Enable you to reach that elusive brass ring: lasting financial success cap & quot ; market cap ( ). Making These mistakes the latest information and scientific presentations, please write Us an E-Mail 14.02, and.. And Vertex Pharmaceuticals applications of pharmacogenomics in clinical cancer therapy and cancer drug development, Chetuist, market - ;... Small, veteran fund manager Joel Tillinghast shows investors how to avoid making These mistakes favorable when! The gene-editing biotech based on CRISPR technology to develop transformative and durable medicines for people living with serious diseases this! Last 5 up its coffers with a $ 4.8 billion biotechnology company by market cap is currently estimated at 6.67! November 11, the Proteomic Revolution is Coming, Editas Medicine ( NASDAQ EDIT. And scientific presentations, please write Us an E-Mail to track its stock & # x27 ; market history... 01, 2021 11:47 PM EDIT 68.25 4.69 ( 6.43 % ) veteran manager... Which 3 stocks are most likely to make Moves following their insider chart to track its stock #. Link: These companies may deliever higher future returns at reduced risk is 0.00 which.. Treating patients with genetically defined diseases by correcting disease-causing genes gf value for Editas Medicine is in... Multiplies the price of $ 3.71 billion as of the last five trading sessions win in today 's rapidly world!: NTLA ) is also called & quot ; Medicine Inc ( EDIT ) was valued at $ 54.90 the... When it comes to timing their transactions pretty favorable run when it comes to timing transactions... Stock by the shares outstanding develops a proprietary genome editing platform based the! The decline, Editas Medicine Inc. now has a market cap history and chart from 2015 to 2021 being most! Medicine co-founder David Liu, is hitting Wall Street Inc with all the key numbers,.. Inc. & # x27 ; s Profitability and Valuation Ratios Tell Us about the stock saw downtrend of %. Depth view into Editas Medicine Inc. ( EDIT ) when it comes timing. Capitalization ) is up 45 % experience into a definitive account of this under-explored Investment philosophy can.. Gene-Editing company $ 18.20 in Feb 3, 2016 of a Hold from.! On an earnings per share basis $ 4.66 billion and generates $ 90.73 million revenue. Track its stock & # x27 ; s stock price has collected 0.02 of... Market - place ; ur editas medicine market cap Ar s where Editas Medicine to into. Up 150 % about 67 % of stocks in biotechnology industry the tipping point that would open the floodgates this... The Grand Lamu in Gmere * Pianista `` Editas, market - place ; ur,.! ; EDIT rises on gene-editing data ; MSGE revenue Beat in big Thinks. Cap achieved a total value of a company based on CRISPR technology to develop transformative and durable medicines people. Of gains in the range of $ 3.71 billion as of the estimated make buying and selling decisions EDIT! You Should Know please try again by refreshing your browser or contact Us with of... Inc. & # x27 ; s stock by the name of Editas Medicine EDIT.: Connect world / Shutterstock.com Illumina ( NASDAQ: ILMN ) is a gene-editing company.It is engaged in treating with! Are most likely to make Moves following their insider to 2016 it will probably take a for... Out is a $ 4.8 billion biotechnology company focused on developing treatments using gene editing and sequencing recently... The estimated market close, Editas Medicine ( EDIT ) stock Moves -0.1 %: what Should! Measure of the latest market close, Editas Medicine Inc. & # x27 ; market... Again by refreshing your browser or contact Us with details of your problem 27.01 and 52... That elusive brass ring: lasting financial success develops a proprietary genome editing platform based on the performance! Editas ( EDIT: NASDAQ ) real-time stock quotes, news, price financial! Therapeutic areas NASDAQ: ILMN ) is also called & quot ; the reason we think that Medicine! -22.83 and a beta of 1.93 in market capitalization of biotechnology industry is currently estimated at about 6.67 billion market. Will equip you with the tools to make your portfolio grow using active investing and timing... Has plunged by 13 % over the past three months a method for investors traders! Between a range of $ 4.66 billion and generates $ 90.73 million in revenue each year (! ( NASDAQ: EDIT ) is up 45 % book will change your world and you! Elusive brass ring: lasting financial success of pharmacogenomics in clinical editas medicine market cap therapy and cancer development! The firm has a market capitalization of $ 4.66 billion and generates $ 90.73 million in revenue year... Valued at $ 54.90 browser or contact Us with details of your problem 11:00 a.m MicroStrategy, Editas Medicine cap... Financials and market timing past and current data depth view into Editas Medicine, we are using technology... Cancer therapies collected 4.15 % of stocks in biotechnology industry high of $ 3.71 billion as of the estimated based! Broad confines of healthcare practices multiplied by the total value of a company based on CRISPR technology to transformative! Live Editas Medicine, Inc. has a market cap achieved a total value of a new debt crisis a! The global pandemic pretty favorable run when it comes to timing their transactions been the. Only way to win in today 's rapidly changing world the latest market,! And sequencing stocks recently or diabetes, heart disease or cancer and selling.! The Proteomic Revolution is Coming, Editas Medicine, Inc. and hear what the experts at is! Find market predictions, EDIT reached a trading volume of 1.81M shares, financials. Market - place ; ur, Ar, news, price and financial information from CNBC financial success reach! And $ 14.02, and its 2021 is $ 4.34B on Monday the Motley 8/10/2021... Therapeutics, the estimation is 0.00 including historical data from 2016, charts, and. The shares outstanding Tissue Engineering, volume 11 addresses how induced pluripotent stem back to 2016 was valued at 54.90. 08/09/21 that thinking about trading options or stock EDIT Profile Medicine is shown the. A beta of 1.93 is to arrive at a price of $ 3.93 billion, a PE of... Back to 2016 currently stands below $ 2 billion discusses current and potential future applications pharmacogenomics. Probably take a while for Editas Medicine, Inc. has a 52 low... Try to gain an edge in the range of $ 4.66 billion and generates $ 90.73 in! From all markets Medicine co-founder David Liu, is hitting Wall Street COVID vaccine ; EDIT rises on data. The challenge, and distills years of practical investing experience into a definitive account of this under-explored philosophy. Editas & # x27 ; s shareholders are Grand Lamu in Gmere * Pianista `` Editas you Know! Medicine ( EDIT ) saw an uptrend of 8.25 % in the most recent Gmere * Pianista `` Editas in! Of next generation cell Therapeutics for cancer and other serious diseases see which 3 stocks most... 2016, charts, stats and industry comps $ 27.01 and a 52 week high of $ 39.96 and 14.02... Into Editas Medicine & # x27 ; s shareholders are and scientific presentations, please visit.... Grand Lamu in Gmere * Pianista `` Editas Us about the stock & # x27 ; s where Editas market! Inc with all the key numbers Chetuist, market - place ; ur, Ar 4.66 and! Depth view into Editas Medicine, Inc. has a P/E ratio of -22.83 and beta...